Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224750 · ClinicalTrials.gov registry record
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
A clinical trial of Cholangiocarcinoma and Colorectal Cancer Screening, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT07224750 is a study of Cholangiocarcinoma and Colorectal Cancer Screening that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 1,000 participants, above the 369-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (171% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07224750, a study of Cholangiocarcinoma and Colorectal Cancer Screening, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies. Current diagnostic approaches-including endoscopy, computed tomography (CT), and magnetic resonance imaging (MRI)-are either invasive, resource-intensive, or insufficiently sensitive for detecting early-stage disease, and are therefore not suitable for population-wide screening or for simultaneously identifying multiple GI tumor types. As a result, many patients are diagnosed at advanced stages, when therapeutic options are limited and prognosis is poor. Circulating microRNAs (miRNAs) offer a promising alternative, as they are stable in peripheral blood and reflect tumor-related molecular alterations. In this study, the investigators aim to develop and validate a robust, noninvasive miRNA-based signature capable of distinguishing GI cancers from non-malignant controls. By integrating multi-cohort datasets and applying machine learning-based feature selection and predictive modeling, the investigators will construct a screening panel optimized for reproducibility, scalability, and early-stage detection. This noninvasive miRNA signature has the potential to support accessible, cost-effective, and clinically practical population-level screening for GI cancers, ultimately facilitating earlier diagnosis and improving outcomes for participants.
Conditions Studied
Study Locations (1)
California
- City of Hope Nat Medical Ctr - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2026-06-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224750
The ClinicalTrials.gov registry entry for NCT07224750 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 369-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (171% higher). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT07224750 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07224750 about?
NCT07224750 is a clinical study titled "A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer". Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies. Current diagnostic approaches-including endoscopy, computed tomography (CT), and magnetic resonance imaging (MRI)-are either invasive, resource-intensive...
What is the current status of trial NCT07224750?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2024-06-21. Estimated completion is 2026-06-18.
What conditions does trial NCT07224750 study?
This clinical trial studies the following conditions: Cholangiocarcinoma, Colorectal Cancer Screening, Pancreatic Ductal Adenocarcinoma (PDAC), Hepatocellular Carcinoma (HCC), Esophageal Squamous Cell Carcinoma (ESCC).
Who is sponsoring clinical trial NCT07224750?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224750 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
RECRUITING · Phase 2
-
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
RECRUITING
-
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RECRUITING · Phase 4
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
-
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.